Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Phototoxicity.

Sensitivity, Contact Clinical Trial

Official title:

Dermatological Assessment of Primary Dermal Irritability Accumulated, Sensitization, Photoallergy and Phototoxicity.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04332445
• Other study ID #: HB032-19
• Status: Completed
• Phase: N/A
• Start date: October 26, 2020
• Est. completion date: December 3, 2020

Study information

• Verified date: November 2021
• Source: Herbarium Laboratorio Botanico Ltda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a clinical study for health care product safety assessment. The research is going to conducted with 55 subjects, aged 18 to 70 years. The product is applied on the right and/or left participant back. After a wash out, the product is reapplied. Medical evaluation will be available throughout the study to assess possible adverse events. The main of the study is to observe the effects of the application of the product on the skin and prove the absence of irritability and/or allergy, photoallergy and phototoxicity.

Description:

Subjects phototypes I to IV (according to Fitzpatrick classification). The products is applied over semi-occlusive dressings, remaing in contact with the skin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: December 3, 2020
• Est. primary completion date: December 3, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Healthy participants;
• Non-injured skin in the test region;
• Agreement to adhere to the test procedures and requirements and to attend the institute on the day(s) and at the time(s) determined for the evaluations;
• Ability to consent to participation in the study;
• Phototype (Fitzpatrick): II and III;

Exclusion Criteria:

• Pregnant or breastfeeding women;
• Use of the following systemic drugs: antihistamines, non-hormonal anti-inflammatory drugs and corticoids;
• History of allergy to cosmetics, topical products or research product;
• Localized or widespread dermatological diseases or inflammatory dermatoses active and nerve damage in the test region;
• Personal or family pathological history of skin cancer;
• Use of topical or systemic photosensitizing medication;
• History of phototoxic, photoallergic reactions, dermatoses caused by light, atopy, pathologies aggravated or triggered by ultraviolet radiation;
• Photo-induced pathologies;
• Frequent exposure to the sun or tanning chambers;
• Participated in an allergenicity study in a period of less than 4 weeks from the start of the study;
• Skin marks in the experimental area that interfere with the evaluation of possible reactions;
• Active dermatoses;
• Forecast to take a bath in the sea, pool or sauna during the study;
• Participants who play water sports;
• Dermography;
• Use of the following topical or systemic drugs: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs and corticoids up to 2 weeks prior to selection or, considering deposit corticoids, the interval shall be 1 month prior to selection;
• Treatment with acid vitamin A and/or its derivatives via oral or topical until 1 month before the beginning of the study;
• Aesthetic and/or body dermatological treatment until 3 weeks before selection;
• Vaccination during the study or until 3 weeks before the study;
• Being participated in another clinical trial.

Related Conditions & MeSH terms

• Dermatitis, Contact
• Dermatitis, Photoallergic
• Dermatitis, Phototoxic
• Sensitivity, Contact

Intervention

Other:
• Hyaluronic Acid Gel
Health care product - to be apllied on the subject's skin

Locations

Country	Name	City	State
Brazil	Kosmoscience Ciência e Tecnologia Cosmética Ltda	Campinas	SP

Sponsors (1)

Lead Sponsor	Collaborator
Herbarium Laboratorio Botanico Ltda

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Erythema degree or absence	Erythema evaluation according to International Contact Dermatitis Research Group	39 days